Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07102316 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants
A Phase 1 study, sponsored by Insmed Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT07102316 is a Phase 1 study that has completed, run by Insmed Incorporated. The registered enrollment target is 42 participants.
The verdict
NCT07102316, a Phase 1 study, has completed, sponsored by Insmed Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the relative bioavailability of treprostinil (TRE) between the TPIP F2 and TPIP F3 at 3 capsule strengths, dose A, dose B, and dose C, in healthy participants following a single inhalation of TPIP dose.
Interventions
- DRUG TPIP F2
- DRUG TPIP F3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2025-08-19 |
| Est. Completion | 2025-11-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07102316
The ClinicalTrials.gov registry entry for NCT07102316 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Insmed Incorporated, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TPIP F2 is the first listed.
NCT07102316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07102316 about?
NCT07102316 is a clinical study titled "A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants". The primary objective of this study is to determine the relative bioavailability of treprostinil (TRE) between the TPIP F2 and TPIP F3 at 3 capsule strengths, dose A, dose B, and dose C, in healthy participants following a single inhalation of TPIP dose.
What is the current status of trial NCT07102316?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2025-08-19. Estimated completion is 2025-11-03.
What interventions are being tested in trial NCT07102316?
The interventions under investigation include: TPIP F2 (DRUG), TPIP F3 (DRUG).
Who is sponsoring clinical trial NCT07102316?
This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.